Affibody: Proprietary Affibody® molecules and Albumod platforms. Lead candidate is an IL-17 with positive Ph2 12wk data in psoriasis. Also has a Ph1 FcRn for b-cell autoimmune diseases partnered with ALXN. Revenue generating from earlier licensed assets. Backed by Investor AB.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Dermatology, Oncology, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Gunnar Asplunds Allé 24, SE-171 69
Stockholm, Stockholms Lan 17169
Sweden

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020